SEC Form 4 · accession 0002050167-26-000019

Maze Therapeutics, Inc. · MAZE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CSBO

Period of report

Jul 29, 2026

Accepted (ET)

Jul 31, 2026 · 4:15 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001842295

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jul 29, 2026	M	7,500	$10.42	A	33,750	D
Common Stock^F2	Jul 29, 2026	S	7,100	$27.3064	D	26,650	D
Common Stock^F3	Jul 29, 2026	S	400	$27.89	D	26,250	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$10.42	Jul 29, 2026	M	7,500	D	—	Apr 11, 2031	Common Stock	7,500	21,643	D

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $27.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.81 to $27.96 per share, inclusive.
F4The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.